Anna C S Tan1, Kunal K Dansingani, Lawrence A Yannuzzi, David Sarraf, K Bailey Freund. 1. *Vitreous Retina Macula Consultants of New York, New York, New York; †LuEsther T Mertz Retinal Research Center, Manhattan, Eye, Ear and Throat Hospital, New York, New York; ‡Singapore National Eye Center/Singapore Eye Research Institute, Singapore, Singapore; §Moorfield Eye Hospital, London, United Kingdom; ¶Truhlsen Eye Institute, University of Nebraska, Omaha, Nebraska; **Stein Eye Institute, University of California, Los Angeles, California; ††Greater Los Angeles VA Healthcare Center, Los Angeles, California; and ‡‡Department of Ophthalmology, New York University School of Medicine, New York, New York.
Abstract
PURPOSE: To study the cross-sectional and en face optical coherence tomography angiography (OCTA) findings in Type 3 neovascularization (NV). METHODS: Optical coherence tomography angiography imaging of 27 eyes of 23 patients with Type 3 NV was analyzed with 9 eyes having consecutive follow-up OCTA studies. RESULTS: Type 3 NV appeared as a linear high-flow structure on cross-sectional OCTA corresponding to a high-flow tuft of vessels seen on en face OCTA. Cross-sectional OCTA seemed to enable the distinction between vascular and nonvascular intraretinal hyperreflective foci. Two patterns of flow were observed; Pattern 1 (11%): a flow signal confined to the neurosensory retina and Pattern 2 (74%): a flow signal extending through the retinal pigment epithelium. No definitive retinal-choroidal anastomosis was observed; however, projection artifacts confounded the interpretation of deeper structures. An increase in the intensity of the high-flow tuft was seen during the progression or recurrence of Type 3 NV. Intravitreal anti-vascular endothelial growth factor therapy caused a reduction in the intensity of the high-flow tuft which was not sustained. CONCLUSION: Compared with conventional imaging, OCTA may improve detection and delineation of vascular changes occurring in Type 3 NV. Cross-sectional and en face OCTA may prove useful in studying the pathogenesis and guiding the management of these lesions.
PURPOSE: To study the cross-sectional and en face optical coherence tomography angiography (OCTA) findings in Type 3 neovascularization (NV). METHODS: Optical coherence tomography angiography imaging of 27 eyes of 23 patients with Type 3 NV was analyzed with 9 eyes having consecutive follow-up OCTA studies. RESULTS: Type 3 NV appeared as a linear high-flow structure on cross-sectional OCTA corresponding to a high-flow tuft of vessels seen on en face OCTA. Cross-sectional OCTA seemed to enable the distinction between vascular and nonvascular intraretinal hyperreflective foci. Two patterns of flow were observed; Pattern 1 (11%): a flow signal confined to the neurosensory retina and Pattern 2 (74%): a flow signal extending through the retinal pigment epithelium. No definitive retinal-choroidal anastomosis was observed; however, projection artifacts confounded the interpretation of deeper structures. An increase in the intensity of the high-flow tuft was seen during the progression or recurrence of Type 3 NV. Intravitreal anti-vascular endothelial growth factor therapy caused a reduction in the intensity of the high-flow tuft which was not sustained. CONCLUSION: Compared with conventional imaging, OCTA may improve detection and delineation of vascular changes occurring in Type 3 NV. Cross-sectional and en face OCTA may prove useful in studying the pathogenesis and guiding the management of these lesions.
Authors: Amir H Kashani; Chieh-Li Chen; Jin K Gahm; Fang Zheng; Grace M Richter; Philip J Rosenfeld; Yonggang Shi; Ruikang K Wang Journal: Prog Retin Eye Res Date: 2017-07-29 Impact factor: 21.198
Authors: Marcus Ang; Anna C S Tan; Chui Ming Gemmy Cheung; Pearse A Keane; Rosa Dolz-Marco; Chelvin C A Sng; Leopold Schmetterer Journal: Graefes Arch Clin Exp Ophthalmol Date: 2018-01-09 Impact factor: 3.117
Authors: Scott M McClintic; Simon Gao; Jie Wang; Ahmed Hagag; Andreas K Lauer; Christina J Flaxel; Kavita Bhavsar; Thomas S Hwang; David Huang; Yali Jia; Steven T Bailey Journal: Ophthalmol Retina Date: 2018-03-02
Authors: Christine A Curcio; Emma C Zanzottera; Thomas Ach; Chandrakumar Balaratnasingam; K Bailey Freund Journal: Invest Ophthalmol Vis Sci Date: 2017-05-01 Impact factor: 4.799
Authors: Atsuro Uchida; Deepa Manjunath; Rishi P Singh; Aleksandra V Rachitskaya; Peter K Kaiser; Sunil K Srivastava; Jamie L Reese; Justis P Ehlers Journal: Ophthalmol Retina Date: 2018-06-14
Authors: A C S Tan; G S Tan; A K Denniston; P A Keane; M Ang; D Milea; U Chakravarthy; C M G Cheung Journal: Eye (Lond) Date: 2017-09-08 Impact factor: 3.775